Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 80,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at $76,848,624.72. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total transaction of $2,435,400.00.

Kymera Therapeutics Trading Down 0.6%

NASDAQ KYMR traded down $0.69 on Thursday, reaching $113.51. 788,284 shares of the stock were exchanged, compared to its average volume of 767,552. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $130.05. The firm has a market capitalization of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95. The company’s 50-day simple moving average is $86.36 and its two-hundred day simple moving average is $82.74.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.82) earnings per share. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on KYMR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Jefferies Financial Group began coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 target price for the company. BTIG Research reissued a “buy” rating and set a $134.00 target price on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Canaccord Genuity Group upped their target price on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Finally, Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $121.41.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC raised its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the 4th quarter worth about $63,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $73,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.